glp-1 agonists contraindications for Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force Clinical Focus on GLP-1 Agonists

The primary goal of this article is to emphasize the extensive benefits of using GLP-1RAs in treating a broad spectrum of diseases, such as obesity, cardiovascular diseases, non-alcoholic fatty liver disease (NAFLD), neurodegenerative diseases, musculoskeletal inflammation, and various forms of cancer

Allulose in human diet: the knowns and the unknowns - Volume 128 Issue 2

While newly approved pharmacotherapies such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) show efficacy, their clinical utility remains constrained by dose-dependent gastrointestinal complications, underscoring the urgent need for safer alternatives

Did you know that individuals using semaglutide experience average weight reductions ranging from 9.6% to 17.4% of their initial body weight

Suggested Caption: What are you hearing about GLP-1 drugs like Ozempic, Wegovy or Mounjaro